Pharmaceutical - Financial, Ophthalmics

Filter

Current filters:

FinancialOphthalmics

Popular Filters

Bayer boasts strong R&D pipeline and growth prospects

03-12-2014

German pharma major Bayer gave a spirited presentation of its pipeline candidates in both pharma and…

AdempasBayerEyleaFinancialHematologyOncologyOphthalmicsPharmaceuticalResearchStivargaXareltoXofigo

NicOx's acquisitions pay off as sales rocket to 4 million euros in third quarter

NicOx's acquisitions pay off as sales rocket to 4 million euros in third quarter

30-10-2014

French pharma company NicOx has achieved sales of 4 million euros ($5 million) in the third quarter of…

FinancialFranceNicOxOphthalmicsPharmaceutical

NicOx and Valeant's glaucoma candidate Vesneo meets Ph III endpoint

NicOx and Valeant's glaucoma candidate Vesneo meets Ph III endpoint

25-09-2014

Canada’s Valeant Pharmaceuticals International and France’s NicOx have reported positive top-line…

Bausch & LombCanadaFinancialFranceNicOxOphthalmicsPharmaceuticalResearchValeant Pharmaceuticals InternationalVesneo

Report shows Eylea and Lucentis are equally likely to be covered by payers

Report shows Eylea and Lucentis are equally likely to be covered by payers

19-09-2014

Recently launched anti-vascular endothelial growth factor (VEGF) agent Eylea (aflibercept), from USA-based…

EyleaFinancialGenentechLucentisOphthalmicsPharmaceuticalRegeneron PharmaceuticalsUSA

Italian legislation undermines EU regulatory framework by endorsing off-label drug use for economic reasons

Italian legislation undermines EU regulatory framework by endorsing off-label drug use for economic reasons

11-06-2014

The European Federation of Pharmaceutical Industries and Associations says it is concerned about a decision…

AvastinEuropeFinancialItalyNovartisOphthalmicsPharmaceuticalRegulationRoche

Avastin could save the USA $29 billion if used instead of Lucentis

Avastin could save the USA $29 billion if used instead of Lucentis

04-06-2014

Using Avastin (bevacizumab) from Swiss drug major Roche instead of Lucentis (ranibizumab) from fellow…

AvastinBevacizumabFinancialLucentisNovartisOphthalmicsPharmaceuticalRocheUSA

Shire 1st-qrt 2014 sales and earnings rocket; lifitegrast disappoints

01-05-2014

Ireland-headquartered drugmaker Shire posted a strong set of financials this afternoon, showing that…

FinancialLifitegrastOphthalmicsPharmaceuticalRare diseasesResearchShire

Roche and Novartis fined for cartelizing sales of eye drugs Avastin and Lucentis in Italy

Roche and Novartis fined for cartelizing sales of eye drugs Avastin and Lucentis in Italy

06-03-2014

Swiss pharma majors Roche and Novartis colluded to exclude the cheaper cancer drug Avastin (bevacizumab),…

AvastinEuropeFinancialItalyLegalLucentisNovartisOphthalmicsPharmaceuticalRoche

Back to top